F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer.

[1]  X. Thuru,et al.  Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma , 2015, Clinical Cancer Research.

[2]  C. Bailly,et al.  Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines. , 2014, Investigational New Drugs.

[3]  C. Bailly,et al.  The antitumor drug F14512 enhances cisplatin and ionizing radiation effects in head and neck squamous carcinoma cell lines. , 2014, Oral oncology.

[4]  J. Annereau,et al.  F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity , 2013, Leukemia.

[5]  B. Monk,et al.  Latest research and treatment of advanced-stage epithelial ovarian cancer , 2013, Nature Reviews Clinical Oncology.

[6]  C. Bailly,et al.  Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II , 2012, Apoptosis.

[7]  R. Bast,et al.  Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. , 2012, Endocrinology.

[8]  J. Annereau,et al.  Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II. , 2011, Biochemical pharmacology.

[9]  Kenneth P. Nephew,et al.  Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.

[10]  N. Osheroff,et al.  Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage. , 2011, Biochemistry.

[11]  C. Bailly,et al.  Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system , 2011, Investigational New Drugs.

[12]  J. Annereau,et al.  A fluorescent biomarker of the polyamine transport system to select patients with AML for F14512 treatment. , 2010, Leukemia research.

[13]  Ya-hong Zhang,et al.  Antitumor conjugates with polyamine vectors and their molecular mechanisms , 2010, Expert opinion on drug delivery.

[14]  A. J. Palmer,et al.  The polyamine transport system as a target for anticancer drug development , 2010, Amino Acids.

[15]  B. Hennessy,et al.  Ovarian cancer , 2009, The Lancet.

[16]  A. Pegg.  Mammalian polyamine metabolism and function , 2009, IUBMB life.

[17]  J. Annereau,et al.  F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system. , 2008, Cancer research.

[18]  Alessandra Montecucco,et al.  Cellular response to etoposide treatment. , 2007, Cancer letters.

[19]  L. Marton,et al.  Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases , 2007, Nature Reviews Drug Discovery.

[20]  O. Gires,et al.  EpCAM (CD326) finding its role in cancer , 2007, British Journal of Cancer.

[21]  M. Inbar,et al.  Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. , 2007, Gynecologic oncology.

[22]  G. Giannini,et al.  Synthesis and cytotoxic activity of polyamine analogues of camptothecin. , 2006, Journal of medicinal chemistry.

[23]  M. Inbar,et al.  Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. , 2004, Gynecologic oncology.

[24]  Steven Sun,et al.  Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. , 2004, Gynecologic oncology.

[25]  A. Tehranian,et al.  Daily low-dose oral etoposide for recurrent epithelial ovarian cancer after platinum-based therapy , 2004, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[26]  K. Kohn,et al.  Apoptosis induced by topoisomerase inhibitors. , 2003, Current medicinal chemistry. Anti-cancer agents.

[27]  R. Ozols.  Ovarian Cancer: American Cancer Society Atlas of Clinical Oncology , 2003 .

[28]  M. Gore,et al.  Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Delcros,et al.  Polyamine transport in mammalian cells. An update. , 1996, The international journal of biochemistry & cell biology.

[30]  P. Cullis,et al.  Targeting of tumor cells and DNA by a chlorambucil-spermidine conjugate. , 1992, Cancer research.

[31]  P. Cullis,et al.  Uptake and cytotoxicity of novel nitroimidazole-polyamine conjugates in Ehrlich ascites tumour cells. , 1992, Biochemical pharmacology.

[32]  M. Oken,et al.  A phase II trial of VP 16–213 in adults with refractory acute myeloid leukemia: An Eastern Cooperative Oncology Group study , 1984, American journal of clinical oncology.

[33]  J. Mandel,et al.  Isolation of mutant mammalian cells altered in polyamine transport , 1978, Journal of cellular physiology.

[34]  I. Smith,et al.  VP 16-213 in acute myelogenous leukaemia , 1976, Postgraduate medical journal.

[35]  J. Misset,et al.  Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas , 1974, Cancer.

[36]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[37]  D. Alberts,et al.  Role of pegylated liposomal doxorubicin in ovarian cancer. , 2005, Gynecologic oncology.

[38]  M. Ratain,et al.  Pharmacodynamics and long-term toxicity of etoposide , 2004, Cancer Chemotherapy and Pharmacology.

[39]  K. Swenerton,et al.  Oral etoposide is active against platinum-resistant epithelial ovarian cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  N. Seiler,et al.  Polyamine transport in mammalian cells. , 1990, The International journal of biochemistry.